IMUX - Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted
2025-06-09 17:51:57 ET
What Happened
On April 30, 2025, Immunic, Inc. (IMUX) provided a readout from its CALLIPER study investigating Vidofludimus Calcium in progressive MS. Following the readout, the stock tanked more than 20%. The stock has continued to falter since the readout, especially after Immunic announced a capital raise on May 29, 2025. For reasons we will discuss, we believe the drop in stock price is unwarranted. We reiterate our Strong Buy rating....
Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted